Compare Teck Resources (TECK) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teck Resources vs Tango Therapeutics Inc. — how do they compare? Teck Resources trades at $64.16 (market cap $31.82B), while Tango Therapeutics Inc. trades at $22.2 (market cap $3.74B). The key difference: Teck Resources is far larger — about 8.5× Tango Therapeutics Inc.'s market cap, and Teck Resources pays a 0.54% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teck Resources for 15 Days and Tango Therapeutics Inc. for 0 Days on average.
| TECK | TNGX | |
|---|---|---|
Market Cap | $31.82B | $3.74B |
Volume | 1,907,858 | 3,438,781 |
Sector | Basic Materials | Health |
52-Week High | $71.97 | $32.90 |
52-Week Low | $38.23 | $7.50 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $34.46B | $2.76B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECK trades at $67.17, down 0.55% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue and net income are projected to grow significantly in 2026, supported by a 17.85% net margin. Analyst consensus is strongly bullish, with 69% buy ratings, amid positive news flow including inclusion in Forbes' top companies for women and copper price optimism.
Outlook remains positive given earnings momentum and copper demand tailwinds, but risks include commodity price volatility and execution of the Anglo American merger. Cash flow turned positive in 2026 forecasts, though 2025 saw a net outflow. The stock offers value with a P/E of 18.82 and EV/EBITDA of 7.77, but investors should monitor merger progress and global economic conditions.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Teck Resources
Teck Resources is a mining company focused on producing metals and minerals, including copper and zinc. Its operations supply materials used in infrastructure, manufacturing, and energy-related industries.
Read more on TECK →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
